Imunon to host R&D day on Sept. 23 for ovarian cancer therapy

Imunon Inc., a clinical-stage biotechnology company based in Lawrenceville, New Jersey, is set to host an R&D Day on September 23, 2026, at the Sofitel New York. This event will be attended by investors, analysts, and media personnel. The focus of the R&D Day will be on Imunon's lead clinical program, IMNN-001, which is a DNA-mediated IL-12 immunotherapy.

The company's press release states that the main presentation will revolve around the pivotal Phase 3 OVATION 3 trial, which is evaluating the efficacy of IMNN-001 in treating women with newly diagnosed advanced ovarian cancer.

In addition to the OVATION 3 trial, discussions will also cover progress and upcoming milestones for this trial, along with insights from a Phase 2 minimal residual disease clinical trial. This trial, conducted in partnership with Break Through Cancer and led by researchers at The University of Texas MD Anderson Cancer Center, is assessing IMNN-001 in patients with minimal residual disease after treatment. A patient who has participated in the clinical trial will share her personal experience and treatment journey.

Details regarding the meeting agenda and the lineup of speakers will be announced in the coming weeks. The event will be live-streamed for virtual attendees. IMNN-001, the subject of the OVATION 3 trial, is an IL-12 DNA plasmid encapsulated in a nanoparticle delivery system developed using Imunon's TheraPlas platform technology.

Positive results from the Phase 2 OVATION 2 Study have been reported by Imunon. This study assessed the effects of IMNN-001 administered intraperitoneally weekly in combination with neoadjuvant and adjuvant chemotherapy versus standard-of-care treatment alone in 112 patients with newly diagnosed advanced ovarian cancer. Imunon's portfolio also includes a first-in-human study of its prophylactic vaccine, IMNN-101.